Biologic Predictors of Leiomyoma Treatment Outcomes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01936493
Recruitment Status : Completed
First Posted : September 6, 2013
Last Update Posted : March 27, 2017
Information provided by (Responsible Party):
Elizabeth A. Stewart, Mayo Clinic

Brief Summary:
The purpose of this study is to search for the hereditary (genetic) causes of uterine fibroids. Some women with uterine fibroids may have one or more genes that make them more likely to develop uterine fibroids. We are trying to identify these genes to better understand how and why uterine fibroids develop and to design better treatment options for women with uterine fibroids. This information may also help us to understand and treat other problems that may be caused by these genes.

Condition or disease Intervention/treatment
Uterine Leiomyomas Fibroids Uterine Fibroids Myomas Genetic: DNA analysis Other: Hormonal analysis

Detailed Description:
There is little information to predict outcomes of leiomyoma therapies. It is clear that both environmental exposures and genetic predisposition influence disease manifestations. Our work has identified a new area of genetic linkage for leiomyomas from a genome wide scan. We therefore propose to prospectively collect biologic samples that will allow us to analyze gene/environment interactions of women enrolled in leiomyoma clinical trials or undergoing leiomyoma clinical treatments using the same methodology used previously. Specifically we will collect serum aliquots, genomic DNA and information using a genetic epidemiology questionnaire. In the short term we will also be able to use prospectively obtained information on epidemiologic and anthropomorphic data to characterize women undergoing treatment.

Study Type : Observational
Actual Enrollment : 38 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Biologic Predictors of Leiomyoma Treatment Outcomes
Study Start Date : August 2009
Actual Primary Completion Date : May 2015
Actual Study Completion Date : May 26, 2015

Group/Cohort Intervention/treatment
Females with uterine fibroids
Participants will be females age of 18 or older who have be diagnosed with uterine leiomyoma. Study Subjects will be asked if mothers or siblings also have diagnosis of uterine leoimyoma (either past or present diagnosis) and these family members will be invited to participate in this trial. All participants will provide blood samples for serum aliquots for hormonal analysis and genomic DNA analysis, and will answer a baseline genetic epidemiology questionnaire.
Genetic: DNA analysis
At a future time DNA analysis will be performed
Other: Hormonal analysis
Participants will provide blood samples so that hormonal factors that influence outcomes of leiomyoma treatments can be assayed.

Primary Outcome Measures :
  1. Analyze environmental exposures and genetic predisposition among women exhibiting disease manifestations of uterine fibroids. [ Time Frame: baseline ]

Biospecimen Retention:   Samples With DNA
Serum aliquots and genomic DNA samples will be collected, processed and stored in the Biospecimen Accessioning Processing (BAP) lab at Mayo Clinic in Rochester, MN.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 99 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients will be enrolled at Mayo Clinic in Rochester, Minnesota. These patients will either be enrolled in leiomyoma clinical trials or undergoing leiomyoma clinical treatment.

Inclusion Criteria:

  1. Able and willing to give consent
  2. Age 18 or older
  3. Presence of known uterine leiomyoma

Exclusion Criteria:

1. Suspected malignancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01936493

United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Elizabeth A. Stewart
Principal Investigator: Elizabeth A. Stewart, M.D. Mayo Clinic - Rochester, Minnesota

Additional Information:
Responsible Party: Elizabeth A. Stewart, Professor of Obstetrics-Gynecology, Mayo Clinic Identifier: NCT01936493     History of Changes
Other Study ID Numbers: 09-003657
First Posted: September 6, 2013    Key Record Dates
Last Update Posted: March 27, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Elizabeth A. Stewart, Mayo Clinic:
Uterine leiomyomas (fibroids or myomas)
Uterine fibroids
Uterine leiomyomas

Additional relevant MeSH terms:
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Connective Tissue Diseases